AlphAIAlphAI — Financial news for AI agents
simplywall.stAUG 193 min read$LEGN

Legend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap?

Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M and net income of $33.2M, reversing a year-earlier loss. The stock has declined 38.5% over 1 year and 68.3% over 3 years, but is up 1.9% year-to-date. Analysts suggest the stock may be undervalued at $21.92, with a fair value estimate of $54.23, citing growth potential in multiple myeloma treatments and expansion opportunities.

Original reporting
simplywall.st
Published Aug 19, 2026, 9:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 7:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Legend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap? — source image
Source · simplywall.st
Decision brief

The 30-second read

$LEGNBullishMed
01

Why it matters

The earnings surprise could trigger a short‑term rally but long‑term performance hinges on pipeline execution.

02

Market read

Earnings news is the primary catalyst for the stock; no broader macro or sector drivers.

03

What to watch

Potential pricing pressure from competitors and upcoming trial readouts could reverse the upside.

Relevance 6/10Novelty 6/10Timing: Q2 2026 earnings released today

Background

Legend Biotech announced its Q2 2026 results, marking a shift from loss to profit.

Company-level read

Ticker impact

$LEGNBullishMedium confidence
Context

Q2 2026 earnings released showing $33.2M net income and $387.5M revenue, a turnaround from a loss a year earlier.

Expected impact

Potential upside of 10‑15% if market digests the profit surprise.

Evidence & confidence

Earnings beat is new information, but the company is small‑cap and the absolute numbers are modest.

Market effects

Sector

Positive earnings may lift sentiment in the biotech AI‑therapy niche.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche investors.

Counterpoint

What could challenge this read

Profit may be temporary; reliance on a single product (CARVYKTI) poses risk.

Key entities

  • Company
    Legend Biotech

    Biotech firm focused on AI‑driven therapies.

Read at source← All news

Related articles

OCT 2
$LEGNHighAI 8/10

Did Five Year CARVYKTI Data Just Shift Legend Biotech's (LEGN) Investment Narrative?

Legend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.

simplywall.st3 min
SEP 25
$LEGNMedAI 8/10

Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma

Legend Biotech (LEGN) reported five-year data from CARTITUDE-2 showing 50% of patients with earlier-line multiple myeloma remained progression-free after a single CARVYKTI infusion. The study, presented at the 2026 IMS Annual Meeting, showed a 69.2% overall survival rate, reinforcing CARVYKTI's potential for durable remission. CARVYKTI is a BCMA-directed cell therapy developed in collaboration with Janssen Biotech.

quiverquant.com2 min
AUG 25
$LEGNHighAI 8/10

Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?

Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.

simplywall.st2 min
AUG 14
$LEGNMedAI 8/10

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657M (+50% YoY), with U.S. $472M (+32%) and ex-U.S. $185M (+128%). Total revenue was $387.5M (+52%), adjusted net income $63.1M ($0.16/share), and cash $965M. Q3 gross margin guidance was lower-50% range.

aol.com6 min